

Literatura ACTA MEDICINAE 9/2017 Vnitřní lékařství

- 2 **Kam směřuje léčba hypertenze**
prof. MUDr. Miroslav Souček, CSc. II. interní klinika a ICRC FN u sv. Anny v Brně a LF MU, Brno
MUDr. Ivan Řiháček, Ph.D. | MUDr. Jan Novák II. interní klinika FN u sv. Anny v Brně a LF MU, Brno
- 2 **Nová doporučení v léčbě srdečního selhání**
prof. MUDr. Jiří Vítovec, CSc. 1. Interní kardiologická klinika, LF MU a FN u Sv. Anny v Brně
prof. MUDr. Jindřich Špinar, CSc., FESC Interní kardiologická klinika, LF MU a FN Brno
prof. MUDr. Lenka Špinarová, Ph.D., FESC 1. Interní kardiologická klinika, LF MU a FN u Sv. Anny v Brně
- 2 **Komentář ke studii PERSPECTIVA**
doc. MUDr. Filip Málek, Ph.D. Kardiovaskulární centrum Nemocnice Na Homolce, Praha
- 2 **Jak léčit srdeční selhání betablokátory**
MUDr. Petr Janský Klinika kardiovaskulární chirurgie 2. LF UK a FN v Motole, Praha
- 3 **Fixní kombinace ACE inhibitoru a blokátoru kalciového kanálu v léčbě hypertenze**
MUDr. Eva Tůmová, Ph.D. Centrum preventivní kardiologie, III. interní klinika 1. LF UK a VFN, Praha
- 3 **Sakubitril/valsartan v léčbě EFLK z pohledu nefrologa**
prof. MUDr. Václav Monhart, CSc. Interní klinika 1. LF UK a ÚVN – Vojenské fakultní nemocnice, Praha; Ambulance nefrologie, Synlab Czech, s. r. o., Praha
- 3 **Mýty a fakta o ACE inhibitech a jejich užití v léčbě a prevenci kardiovaskulárních onemocnění**
MUDr. Libor Jelínek | doc. MUDr. Jan Václavík, Ph.D., FESC I. interní klinika – kardiologická, FN Olomouc
- 4 **Komentář ke studii DUAL VII**
MUDr. Jindřich Olšovský, Ph.D. II. interní klinika LF MU a FN u sv. Anny v Brně
- 4 **Farmakokinetika a farmakodynamika nových dlouhodobě působících inzulinů a jejich význam pro klinickou praxi**
prof. MUDr. Martin Haluzík, DrSc. Centrum diabetologie a Centrum experimentální medicíny, IKEM; Endokrinologický ústav; ÚLBLD 1. LF UK a VFN, Praha
- 5 **Fenomén úsvitu**
prof. MUDr. Kateřina Štechová, Ph.D. Interní klinika FN v Motole, Praha
- 5 **Ezetimib, jeho účinky a uplatnění v léčbě dyslipidemií**
prof. MUDr. Hana Rosolová, DrSc. Centrum preventivní kardiologie, II. interní klinika FN a UK, Plzeň
- 5 **Úspěchy v léčbě dyslipoproteinemií**
prof. MUDr. Helena Vavřková, CSc. III. interní klinika – nefrologická, revmatologická a endokrinologická, LF UP a FN Olomouc
- 6 **Antikoagulační léčba hluboké žilní trombózy a plicní embolie**
doc. MUDr. Jaromír Chlumský, Ph.D. Interní klinika 2. LF UK a FN Motol, Praha
- 6 **Léčba akutní ischemické cévní mozkové příhody**
MUDr. Jaroslava Paulasová Schwabová, Ph.D. Neurologická klinika 2. LF UK a FN Motol, Laboratoř sportovní motoriky, Fakulta tělesné výchovy a sportu UK, Praha MUDr. Aleš Tomek, Ph.D., FESO Neurologická klinika 2. LF UK a FN Motol, Praha
- 7 **Dna – častý problém, léčebné možnosti**
doc. MUDr. Petr Němec, Ph.D. Revmatologická ambulance II. interní kliniky, FN u sv. Anny v Brně a LF MU, Brno
- 7 **Význam kolchicinu v akutní a dlouhodobé terapii dny**
doc. MUDr. Petr Bradna, CSc. II. interní gastroenterologická klinika, subkatedra revmatologie, LF a FN Hradec Králové
- 7 **Střevní mikrobiota**
doc. MUDr. Darina Kohoutová, Ph.D. | prof. MUDr. Jan Bureš, CSc., FCMA
II. interní gastroenterologická klinika, LF UK a FN Hradec Králové
- 8 **Novinky ve farmakoterapii bolesti**
MUDr. Marek Hakl, Ph.D. Klinika algeziologie a preventivní péče, Medicinicare, s. r. o., Chirurgická klinika FN Brno a LF MU, Brno
- 8 **Přínos suché krevní kapky v diagnostice dědičných metabolických onemocnění**
Ing. Karolína Pešková Klinika dětského a dorostového lékařství VFN a 1. LF UK, Praha
- 8 **Extrahepatální manifestace infekce HCV**
prof. MUDr. Petr Husa, CSc. Klinika infekčních chorob LF MU a FN Brno
- 9 **Diagnostika a medikamentózní terapie exokrinní pankreatické nedostatečnosti u osob s chronickou pankreatitidou v ČR – dle UEG doporučení**
prof. MUDr. Petr Dítě, DrSc. | MUDr. Martin Blaho Interní klinika Fakultní nemocnice Ostrava, Lékařská fakulta Ostravské Univerzity, Ostrava MUDr. Martina Bojková | MUDr. Tomáš Kuka Interní klinika Fakultní nemocnice Ostrava

Kam směřuje léčba hypertenze

prof. MUDr. Miroslav Souček, CSc. II. interní klinika a ICRC FN u sv. Anny v Brně a LF MU, Brno
MUDr. Ivan Řiháček, Ph.D. | MUDr. Jan Novák II. interní klinika FN u sv. Anny v Brně a LF MU, Brno

- 1 Wright, J. M. – Musini, V. M.: First-line drugs for hypertension. *Cochrane Database Syst Rev*, 2009, 3, s. CD001841.
- 2 Lindholm, L. H. – Carlberg, B. – Samuelsson, O.: Should beta-blockers remain first choice in the treatment of arterial hypertension? A meta-analysis. *Lancet*, 2005, 366, s. 1545–1553.
- 3 Filipovský, J. – Widimský, J. jr. – Ceral, J., et al.: Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi ČLS JEP. *Vnitřní Léč*, 2012, 58, s. 785–801.
- 4 Hradec, J.: Kontroverze kolem betablokátorů. *Vnitřní Léč*, 2015, 61, s. 410–416.
- 5 Dorsch, M. P. – Gillespie, B. W. – Erickson, S. R., et al.: Chlorthalidone Reduces cardiovascular events compared with hydrochlorothiazide; a retrospective cohort analysis. *Hypertension*, 2011, 57, s. 689–694.
- 6 Wald, D. S. – Law, M. – Morris, J. K., et al.: Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. *Am J Med*, 2009, 122, s. 290–300.
- 7 Jamerson, K. – Weber, M. A. – Bakris, G. L., et al.: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *N Engl J Med*, 2008, 359, s. 2417–2428.
- 8 Frank, J.: Managing hypertension using combination therapy. *Am Fam Physician*, 2008, 77, s. 1279–1286.
- 9 Egan, B. M. – Bandyopadhyay, D. – Shaftman, S. R., et al.: Initial monotherapy and combination therapy and hypertension control the first year. *Hypertension*, 2012, 59, s. 1124–1131.
- 10 Kociánová, E. – Václavík, J. – Táborský, M.: Fixní kombinace v léčbě hypertenze – přehled současných možností. *Kardiologie výběr článků*, 2014, s. 19–22.
- 11 Bangalore, S. – Kamalakkannan, G. – Parkar, S., et al.: Fixed-dose combinations improve medication compliance: a meta-analysis. *Am J Med*, 2007, 120, s. 713–719.
- 12 Mancia, G. – Fagard, R. – Narkiewicz, K., et al.: ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J*, 2013, 34, s. 2159–2219.
- 13 Chalmers, J. – Arima, H. – Woodward, M., et al.: Effects of combination perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus. Results from the Action in Diabetes and Vascular Disease: Preterax and Diamicon Controlled Evaluation (ADVANCE) Trial. *Hypertension*, 2014, 63, s. 259–264.
- 14 Toth, K., and Investigators: Antihypertensive efficacy of triple combination Perindopril/Indapamide plus Amlodipine in high-risk hypertensive: Results of the PIANIST Study. *Am J Cardiovasc Drug*, 2014, 14, s. 239–239.
- 15 Pall, D. – Szanto, I. – Szabo Z.: Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. *Clin Drug Invest*, 2014, 34, s. 701–708.

Nová doporučení v léčbě srdečního selhání

prof. MUDr. Jiří Vítovec, CSc. 1. Interní kardiologická klinika, LF MU a FN u Sv. Anny v Brně
prof. MUDr. Jindřich Špinar, CSc., FESC Interní kardiologická klinika, LF MU a FN Brno
prof. MUDr. Lenka Špinarová, Ph.D., FESC 1. Interní kardiologická klinika, LF MU a FN u Sv. Anny v Brně

- 1 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*, 2016, 37, s. 2129–2200.
- 2 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure – Web Addenda. *Eur Heart J*, 2016, 37, doi:10.1093/eurheartj/ehw128.
- 3 Špinar, J. – Hradec, J. – Špinarová, L. – Vítovec, J.: Summary of the 2016 ESC Guidelines on the diagnosis and treatment of acute and chronic heart failure. Prepared by the Czech Society of Cardiology. *Cor et Vasa*, 2016, 58, s. e530–e568.
- 4 Špinar, J.: Komentář k Doporučeným postupům ESC/ ČKS. Farmakoterapie srdečního selhání. *Kardiolog Rev Int Med*, 2016, 18, s. 234–239.

Komentář ke studii PERSPECTIVA

doc. MUDr. Filip Málek, Ph.D. Kardiologické centrum Nemocnice Na Homolce, Praha

- 1 Sirenko, Y. – Radchenko, G.; PERSPECTIVA study group: Impact of statin therapy on the blood pressure-lowering efficacy of a single-pill perindopril/amlodipine combination in hypertensive patients with hypercholesterolemia high blood press. *Cardiovasc Prev*, 2017, DOI 10.1007/s40292-017-0184-5.
- 2 Kanaki, A. I. – Sarafidis, P. A. – Georgianos, P. I., et al.: Low-dose atorvastatin reduces ambulatory blood pressure in patients with mild hypertension and hypercholesterolemia: a double-blind, randomized, placebo-controlled study. *J Hum Hypertens*, 2012, 26, s. 577–584.
- 3 Correa, V. – Fuchs, F. D. – Moreira, L. B., et al.: Blood pressure-lowering effect of simvastatin: a placebo-controlled randomized clinical trial with 24-h ambulatory blood pressure monitoring. *J Hum Hypertens*, 2014, 28, s. 62–67.
- 4 Mancia, G. – Parati, G. – Revere, M., et al.: Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial. *BMJ*, 2010, 340, s. c1197.
- 5 Strazzullo, P. – Kerry, S. M. – Barbato, A., et al.: Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials. *Hypertension*, 2007, 49, s. 792–798.
- 6 Sever, P. S. – Dahlöf, B. – Poulter, N. R., et al.; ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet*, 2003, 361, s. 1149–1158.
- 7 Kamberi, L. S. – Bedri Bakalli, A., et al.: Pleiotropic and lipidlowering effects of statins in hypertension. *Mater Sociomed*, 2012, 24, s. 84–86.
- 8 Filipovský, J. – Widimský, J. jr. – Ceral, J., et al.: Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi. *Hypertenze a kardiologická prevence*, 2012, 3, s. 1–16.
- 9 Soška, V. – Vavřková, H. – Vrablík, M., et al.: Stanovisko výboru ČSAT k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2011. *Vnitřní Léč*, 2013, 59, s. 120–126.
- 10 Bertrand, M. E. – Vlachopoulos, Ch. – Mourad, J. J.: Triple combination therapy for global cardiovascular risk: atorvastatin, perindopril, and amlodipin. *Am J Cardiovasc Drugs*, 2016, 16, s. 241–253.

Jak léčit srdeční selhání betablokátorů

MUDr. Petr Janský Klinika kardiologické chirurgie 2. LF UK a FN v Motole, Praha

- 1 Wieselgren, I. – Lundborg, P. – Sandberg, A., et al.: Pharmacokinetic and pharmacodynamic evaluation of metoprolol controlled release (CR/ZOK) 50 mg in young subjects. *J Clin Pharmacol*, 1990, 30, suppl, s. S28–S32.
- 2 Chadda, K. – Goldstein, S. – Byington, R., et al.: Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. *Circulation*, 1986, 73, s. 503–510.
- 3 Norwegian Multicenter Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. *N Engl J Med*, 1981, 304, s. 801–807.
- 4 Waagstein, F. – Bristow, M. R. – Swedberg, K., et al.: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC). Trial Study Group. *Lancet*, 1993, 342, s. 1441–1446.
- 5 [No authors listed]: A randomized trial of beta blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. *Circulation*, 1994, 90, s. 1765–1773.
- 6 Packer, M. – Bristow, M. R. – Cohn, J. N., et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U. S. Carvedilol Heart Failure Study Group. *N Engl J Med*, 1996, 334, s. 1349–1355.
- 7 Dargie, H. J.: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. *Lancet*, 2001, 357, s. 1385–1390.
- 8 Packer, M. – Coats, A. J. – Fowler, M. B., et al.; Carvedilol Prospective Randomized Cumulative Survival Study Group: Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med*, 2001, 344, s. 1651–1658.
- 9 [No authors listed]: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet*, 1999, 353, s. 2001–2007.
- 10 [No authors listed]: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *Lancet*, 1999, 353, s. 9–13.
- 11 Flather, M. D. – Shibata, M. C. – Coats, A. J., et al.: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J*, 2005, 26, s. 215–225.
- 12 Poole-Wilson, P. A. – Swedberg, K. – Cleland, J. G., et al.: Comparison of carvedilol and metoprolol on clinical outcomes in patients with

chronic heart failure in the Carvedilol Or Metoprolol (COMET): randomised controlled trial. *Lancet*, 2003, 362, s. 7–13.

13 **Ponikowski, P. – Voors, A. A. – Anker, S. D., et al.**: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task

Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J*, 2016, 37, s. 2129–2200.

14 **Kotecha, D. – Holmes, J. – Krum, H., et al.**: Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. *Lancet*, 2014, 384, s. 2235–2243.

Fixní kombinace ACE inhibitoru a blokátoru kalciového kanálu v léčbě hypertenze

MUDr. Eva Tůmová, Ph.D. Centrum preventivní kardiologie, III. interní klinika 1. LF UK a VFN, Praha

- 1 **Yusuf, S. – Sleight, P. – Pogue, J., et al.**: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med*, 2000, 342, s. 145–153.
- 2 **Fox, K. M.**: EUROpean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet*, 2003, 362, s. 782–788.
- 3 **Pilote, L. – Abrahamowicz, M. – Rodrigues, E., et al.**: Mortality rates in elderly patients who take different angiotensin converting enzyme inhibitors after acute myocardial infarction: a class effect? *Ann Intern Med*, 2004, 141, s. 102–112.
- 4 **Pilote, L. – Abrahamowicz, M. – Eisenberg, M., et al.**: Effect of different angiotensin converting enzyme inhibitors on mortality among elderly patients with congestive heart failure. *CMAJ*, 2008, 178, s. 1303–1311.
- 5 **Filipovský, J. – Widimský jr., J. – Ceral, J., et al.**: Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi – verze 2012. *Vnitřní Lékař*, 2012, 58, s. 785–801.
- 6 **Jamerson, K. – Weber, M. A. – Bakris, G. L., et al.**: ACCOMPLISH Trial Investigators: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *N Engl J Med*, 2008, 359, s. 2417–2428, doi: 10.1056/NEJMoa0806182.
- 7 **Simonyi, G. – Ferenci, T.**: Medication adherence with the fixed combination of ramipril and amlodipine. *Orv Hetil*, 2014, 155, s. 1882–1888, doi: 10.1556/OH.2014.30037.

Sakubitril/valsartan v léčbě EFLK z pohledu nefrologa

prof. MUDr. Václav Monhart, CSc. Interní klinika 1. LF UK a ÚVN – Vojenské fakultní nemocnice, Praha; Ambulance nefrologie, Synlab Czech, s. r. o., Praha

- 1 **Ponikowski, P. – Voors, A. A. – Anker, S. D., et al.**: Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail*, 2016, 18, s. 891–975.
- 2 **McMurray, J. J.**: Nephrylsin inhibition to treat heart failure: a tale of science, serendipity, and second chances. *Eur J Heart Fail*, 2015, 17, s. 242–247.
- 3 SPC Entresto. Státní ústav pro kontrolu léčiv, 2016. Dostupné z: <http://www.sukl.cz/modules/medication/detail.php?code=0209042>, vyhledáno 13. 9. 2017.
- 4 **Packer, M. – McMurray, J. J. – Desai, A. S., et al.**: for the PARADIGM-HF Investigators and Coordinators: Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. *Circulation*, 2015, 131, s. 54–61.
- 5 **McMurray, J. J.**: Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). *Eur J Heart Fail*, 2013, 15, s. 1062–1073.
- 6 **McMurray, J. J. – Packer, M. – Desai, A. S., et al.**: Angiotensin-neprilysin inhibition vs enalapril in heart failure. *N Engl J Med*, 2014, 371, s. 993–1004.
- 7 **Špinar, J. – Hradec, J. – Špinarová, L. – Vitovec, J.**: Souhrn doporučených postupů pro diagnostiku a léčbu akutního a chronického srdečního selhání z roku 2016. Přípraven Českou kardiologickou společností. *Cor Vasa*, 2016, 58, s. 597–636.
- 8 **Chen, J. – Ross, J. S. – Carlson, M. D., et al.**: Skilled nursing facility referral and hospital readmission rates after heart failure or myocardial infarction. *Am J Med*, 2012, 125, s. 100, e1–100.e9.
- 9 **Okumura, N. – Jhund, P. S. – Gong, J., et al.**: Importance of clinical worsening of heart failure treated in the outpatient setting: Evidence from the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). *Circulation*, 2016, 133, s. 2254–2262.

Mýty a fakta o ACE inhibitorech a jejich užití v léčbě a prevenci kardiovaskulárních onemocnění

MUDr. Libor Jelínek | doc. MUDr. Jan Václavík, Ph.D., FESC
I. interní klinika – kardiologická, FN Olomouc

- 1 **Campbell, J. A. – Lamar, W. W.**: *The venomous reptiles of the Western Hemisphere*. Ithaca: Comstock Pub. Associates, 2004.
- 2 SPC přípravku Tensiomin. Dostupné z: <http://www.sukl.cz/modules/medication/detail.php?code=0049564&tab=texts>, vyhledáno 13. 10. 2017.
- 3 **Kagan, A. – Gordon, T. – Kannel, W. B., et al.**: Blood pressure and its relation to coronary heart disease in the Framingham Study; Hypertension Volume VII. *Drug Action, Epidemiology and Hemodynamics. Proceedings of the Council for High Blood Pressure Research, American Heart Association*. New York, American Heart Association, 1959, s. 53–81.
- 4 **Dimmler, S. – Rippmann, V. – Weiland, U., et al.**: Angiotensin II Induces apoptosis of human endothelial cells: protective effect of nitric oxide. *Circulation Research*, 1997, 81, s. 970–976, DOI: 10.1161/01.RES.81.6.970, dostupné z: <http://circres.ahajournals.org/cgi/doi/10.1161/01.RES.81.6.970>, vyhledáno 26. 9. 2017.
- 5 **Probstfeld, J. L. – O'Brien, K. D.**: Progression of cardiovascular damage: the role of renin-angiotensin system blockade. *Am J Cardiol*, 2010, 105, s. 10A–20A, DOI: 10.1016/j.amjcard.2009.10.006, dostupné z: <http://linkinghub.elsevier.com/retrieve/pii/S0002914909024813>, vyhledáno 26. 9. 2017.
- 6 **Ferrari, R. – Boersma, E.**: The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review. *Exp Rev Cardiovasc Ther*, 2014, 11, s. 705–717, DOI: 10.1586/erc.13.42, dostupné z: <http://www.tandfonline.com/doi/full/10.1586/erc.13.42>, vyhledáno 28. 9. 2017.
- 7 **Agostoni, A. – Cicardi, M.**: Drug-induced angioedema without urticaria. *Drug Saf*, 2001, 24, s. 599–606.
- 8 **Banerji, A. – Blumenthal, K. G. – Lai, K. H., et al.**: Epidemiology of ACE inhibitor angioedema utilizing a large electronic health record. *J Allergy Clin Immunol*, 2017, 5, s. 744–749, DOI: 10.1016/j.jaip.2017.02.018, dostupné z: <http://linkinghub.elsevier.com/retrieve/pii/S2213219817301630>, vyhledáno 28. 9. 2017.
- 9 **Morimoto, T. – Gandhi, T. K. – Fiskio, J. M., et al.**: An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. *J Eval Clin Pract*, 2004, 10, s. 499–509, DOI: 10.1111/j.1365-2753.2003.00484.x, dostupné z: <http://doi.wiley.com/10.1111/j.1365-2753.2003.00484.x>, vyhledáno 28. 9. 2017.
- 10 **Cecconi, C. – Fox, K. – Remme, W., et al.**: ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. *Cardiovasc Res*, 2007, 73, s. 237–246, DOI: 10.1016/j.cardiores.2006.10.021, dostupné z: <https://academic.oup.com/cardiovascres/article-lookup/doi/10.1016/j.cardiores.2006.10.021>, vyhledáno 30. 9. 2017.
- 11 **Tumanan-Mendoza, B. A. – Dans, A. L. – Villacin, L. L., et al.**: Dechallenge and rechallenge method showed different incidences of cough among four ACE-Is. *J Clin Epidemiol*, 2007, 60, s. 547–553, DOI: 10.1016/j.jclinepi.2006.06.017, ISSN 08954356, dostupné z: <http://linkinghub.elsevier.com/retrieve/pii/S0895435606002617>, vyhledáno 30. 9. 2017.
- 12 **Israilli, Z. H. – Hall, W. D.**: Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. *Ann Intern Med*, 1992, 117, s. 234–242, DOI: 10.7326/0003-4819-117-3-234, dostupné z: <http://annals.org/article.aspx?doi=10.7326/0003-4819-117-3-234>, vyhledáno 13. 10. 2017.
- 13 **Soares, I. – Carneiro, A.**: Efeitos de Classe de Medicamentos: Definição e Aplicações Práticas. *Rev Port Cardiol*, 2002, 21, s. 1031–1042.
- 14 **Zannad, F. – Zukaï, Ch. – Guest, M., et al.**: Differential effects of fasinopril and enalapril in patients with mild to moderate chronic heart failure. *Rev Port Cardiol*, 2002, 21, s. 1031–1042, DOI: 10.1016/S0002-8703(98)70015-8, dostupné z: <http://linkinghub.elsevier.com/retrieve/pii/S0002870398700158>, vyhledáno 28. 9. 2017.
- 15 **Greenbaum, R. – Zuchelli, P. – Caspi, A., et al.**: Comparison of the pharmacokinetics of fasinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency. *Brit J Clin Pharmacol*, 2000, 49, s. 23–31, DOI: 10.1046/j.1365-2125.2000.00103.x, dostupné z: <http://doi.wiley.com/10.1046/j.1365-2125.2000.00103.x>, vyhledáno 29. 9. 2017.
- 16 **Cecconi, C. – Francolini, G. – Olivarez, A., et al.**: Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin

- binding sites of human somatic ACE. *Eur J Pharmacol*, 2007, 577, s. 1–6, DOI: 10.1016/j.ejphar.2007.07.061, dostupné z: <http://linkinghub.elsevier.com/retrieve/pii/S0014299907008540>, vyhledáno 7. 10. 2017.
- 17 **Dinicolantonio, J. J. – Lavie, C. J. – O’Keefe, H.**: Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril. *Postgraduate Medicine*, 2015, 125, s. 154–168, DOI: 10.3810/pgm.2013.07.2687, dostupné z: <http://www.tandfonline.com/doi/full/10.3810/pgm.2013.07.2687>, vyhledáno 7. 10. 2017.
- 18 **Pilote, L. – Abrahamowicz, M. – Rodrigues, E., et al.**: Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: A class effect? *An Intern Med*, 2004, 141, s. 102–112, DOI: 10.7326/0003-4819-141-2-200407200-00008, dostupné z: <http://annals.org/article.aspx?doi=10.7326/0003-4819-141-2-200407200-00008>, vyhledáno 10. 10. 2017.
- 19 **Ishida, J. – Konishi, M. – Von Haehling, S.**: The appropriate dose of angiotensin-converting-enzyme inhibitors or angiotensin receptor blockers in patients with dilated cardiomyopathy. The higher, the better? *ESC Heart Failure*, 2015, 2, s. 103–105, DOI: 10.1002/ehf2.12073, dostupné z: <http://doi.wiley.com/10.1002/ehf2.12073>, vyhledáno 28. 9. 2017.
- 20 **McMullan, R.**: A survey of the dose of ACE inhibitors prescribed by general physicians for patients with heart failure. *Postgrad Med J*, 2001, 77, s. 765–768, DOI: 10.1136/pmj.77.914.765, dostupné z: <http://pmj.bmj.com/cgi/doi/10.1136/pmj.77.914.765>, vyhledáno 30. 9. 2017.
- 21 **Taddei, S.**: RAS inhibitors’ dose-dependent efficacy: myth or reality? *Cur Med Res Opin*, 2015, 31, s. 1245–1256, DOI: 10.1185/03007995.2015.1053047, dostupné z: <http://www.tandfonline.com/doi/full/10.1185/03007995.2015.1053047>, vyhledáno 28. 9. 2017.
- 22 **Ceral, J. – Habrdova, V. – Vorisek, V., et al.**: Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. *Hypertens Res*, 2010, 34, s. 87–90, DOI: 10.1038/hr.2010.183, dostupné z: <http://www.nature.com/doi/10.1038/hr.2010.183>, vyhledáno 5. 10. 2017.
- 23 **Bangalore, S. – Kamalakkannan, G. – Parkar, S., et al.**: Fixed-dose combinations improve medication compliance: a meta-analysis. *Am J Med*, 2007, 120, s. 713–719, DOI: 10.1016/j.amjmed.2006.08.033, dostupné z: <http://linkinghub.elsevier.com/retrieve/pii/S000293430601151X>, vyhledáno 5. 10. 2017.
- 24 Dostupné z: https://es.wikipedia.org/wiki/Bothrops_jararaca#/media/File:Bothrops_jararaca_descansando_na_trilha.JPG, publikováno dle licence CC BY-SA 4.0, vyhledáno 13. 10. 2017.
- 25 Studie HOPE: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *New Eng J Med*, 2000, 342, s. 145–153, DOI: 10.1056/NEJM20001203420301, dostupné z: <http://www.nejm.org/doi/abs/10.1056/NEJM20001203420301>, vyhledáno 13. 10. 2017.
- 26 Studie EUROPA: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet*, 2003, 362, s. 782–788, DOI: 10.1016/S0140-6736(03)14286-9, dostupné z: <http://linkinghub.elsevier.com/retrieve/pii/S0140673603142869>, vyhledáno 13. 10. 2017.
- 27 Studie QUIET: **Pitt, B. – O’Neil, B. – Feldman, R., et al.**: The Quinapril Ischemic Event Trial (QUIET): evaluation of chronic ace inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. *Am J Cardiol*, 2001, 87, s. 1058–1063, DOI: 10.1016/S0002-9149(01)01461-8, dostupné z: <http://linkinghub.elsevier.com/retrieve/pii/S0002914901014618>, vyhledáno 13. 10. 2017.
- 28 Studie PEACE: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. *New Eng J Med*, 2004, 351, s. 2058–2068, DOI: 10.1056/NEJMoa042739, dostupné z: <http://www.nejm.org/doi/abs/10.1056/NEJMoa042739>, vyhledáno 13. 10. 2017.

Komentář ke studii DUAL VII

MUDr. Jindřich Olšovský, Ph.D. II. interní klinika LF MU a FN u sv. Anny v Brně

- 1 **Inzucchi, S. E. – Bergenstal, R. M. – Buse, J. B., et al.**: Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetologia*, 2015, 58, s. 429–442.
- 2 DUAL VII trial (NCT02420262): Efficacy and safety of insulin degludec/liraglutide (IDegLira) versus basal-bolus (BB) therapy in patients with type 2 diabetes (T2D), ADA, 10. 6. 2017, přednáška (136-OR).
- 3 **Marso, S. P. – Daniels, G. H. – Brown-Frandsen, K., et al.**: Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*, 2016, 375, s. 311–322.

Farmakokinetika a farmakodynamika nových dlouhodobě působících inzulinů a jejich význam pro klinickou praxi

prof. MUDr. Martin Haluzík, DrSc. Centrum diabetologie a Centrum experimentální medicíny, IKEM; Endokrinologický ústav; ÚLBLD 1. LF UK a VFN, Praha

- 1 **Wright, A. – Burden, A. C. – Paisey, R. B., et al.**: Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). *Diabetes Care*, 2002, 25, s. 330–336.
- 2 **Inzucchi, S. E. – Bergenstal, R. M. – Buse, J. B., et al.**: Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*, 2012, 35, s. 1364–1379.
- 3 **Inzucchi, S. E. – Bergenstal, R. M. – Buse, J. B., et al.**: Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*, 2015, 38, s. 140–149.
- 4 **Weng, J. – Li, Y. – Xu, W., et al.**: Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. *Lancet*, 2008, 371, s. 1753–1760.
- 5 **ORIGIN Trial Investigators, Gerstein, H. C. – Bosch, J. – Dagenais, G. R., et al.**: Basal insulin and cardiovascular and other outcomes in dysglycemia. *N Engl J Med*, 2012, 367, s. 319–238.
- 6 **Holman, R. R. – Paul, S. K. – Bethel, M. A., et al.**: 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med*, 2008, 359, s. 1577–1589.
- 7 **Calvert, M. J. – McManus, R. J. – Freemantle, N.**: Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. *Br J Gen Pract*, 2007, 57, s. 455–460.
- 8 **Simons, W. R. – Vinod, H. D. – Gerber, R. A., et al.**: Does rapid transition to insulin therapy in subjects with newly diagnosed type 2 diabetes mellitus benefit glycaemic control and diabetes-related complications? A German population-based study. *Exp Clin Endocrinol Diabetes*, 2006, 114, s. 520–526.
- 9 **Baldeweg, S. E. – Yudkin, J. S.**: Implications of the United Kingdom prospective diabetes study. *Prim Care*, 1999, 26, s. 809–827.
- 10 **Haak, T. – Tiengo, A. – Draeger, E., et al.**: Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. *Diabetes Obes Metab*, 2005, 7, s. 56–64.
- 11 **Yki-Jarvinen, H. – Dressler, A. – Ziemer, M.**: Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. *Diabetes Care*, 2000, 23, s. 1130–1136.
- 12 **Evans, M. – Schumm-Draeger, P. M. – Vora, J., et al.**: A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. *Diabetes Obes Metab*, 2011, 13, s. 677–684.
- 13 **Zachariah, S. – Sheldon, B. – Shojaae-Moradie, F., et al.**: Insulin detemir reduces weight gain as a result of reduced food intake in patients with type 1 diabetes. *Diabetes Care*, 2011, 34, s. 1487–1491.
- 14 **Sutton, G. – Minguet, J. – Ferrero, C., et al.**: U300, a novel long-acting insulin formulation. *Expert Opin Biol Ther*, 2014, 14, s. 1849–1860.
- 15 **Polimeni, G. – Trifiro, G. – Ingrassiotta, Y., et al.**: The advent of biosimilars for the treatment of diabetes: current status and future directions. *Acta Diabetologica*, 2015, 52, s. 423–431.
- 16 **Khunti, K. – Cos, X. – Rutten, G.**: Insulin degludec—the impact of a new basal insulin on care in type 2 diabetes. *Prim Care Diabetes*, 2014, 8, s. 119–125.
- 17 **Heinemann, L. – Richter, B.**: Clinical pharmacology of human insulin. *Diabetes Care*, 1993, 16, suppl. 3, s. 90–100.
- 18 **Mathieu, C.**: Can we reduce hypoglycaemia with insulin detemir? *Int J Obes Relat Metab Disord*, 2004, 28, suppl. 2, s. 35–40.
- 19 **Dunn, C. J. – Plosker, G. L. – Keating, G. M., et al.**: Insulin glargine: an updated review of its use in the management of diabetes mellitus. *Drugs*, 2003, 63, s. 1743–1778.
- 20 **Gough, S. C. – Harris, S. – Woo, V., et al.**: Insulin degludec: Overview of a novel ultra long-acting basal insulin. *Diabetes Obes Metab*, 2013, 15, s. 301–309.
- 21 **Jonassen, I. – Havelund, S. – Hoeg-Jensen, T., et al.**: Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. *Pharm Res*, 2012, 29, s. 2104–2114.
- 22 **Heise, T. – Nosek, L. – Bottcher, S. G., et al.**: Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. *Diabetes Obes Metab*, 2012, 14, s. 944–950.
- 23 **Goldman-Levine, J. D. – Patel, D. K. – Schnee, D. M.**: Insulin degludec: a novel basal insulin analogue. *Ann Pharmacother*, 2013, 47, s. 269–277.
- 24 **Mathieu, C. – Hollander, P. – Miranda-Palma, B., et al.**: Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. *J Clin Endocrinol Metab*, 2013, 98, s. 1154–1162.
- 25 **Ritzel, R. – Rousset, R. – Bolli, G. B., et al.**: Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. *Diabetes Obes Metab*, 2015, 17, s. 859–867.
- 26 **Yki-Jarvinen, H. – Bergenstal, R. M. – Bolli, G. B., et al.**: Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs (EDITION 2 randomised 12-month trial including 6-month extension). *Diabetes Obes Metab*, 2015, 17, s. 1142–1149.
- 27 **Riddle, M. C. – Bolli, G. B. – Home, P. D., et al.**: Efficacy and safety of flexible versus fixed dosing intervals of insulin glargine 300 U/ml in people with type 2 diabetes. *Diabetes Technol Ther*, 2016, 18, s. 252–257.
- 28 **Heise, T. – Zijlstra, E. – Nosek, L., et al.**: Euglycaemic glucose clamp: what it can and cannot do, and how to do it. *Diabetes Obes Metab*, 2016, 18, s. 962–972.
- 29 **DeFronzo, R. A. – Tobin, J. D. – Andres, R.**: Glucose clamp technique: a method for quantifying insulin secretion and resistance. *Am J Physiol*, 1979, 237, s. E214–223.
- 30 **Wohl, P. – Krusinova, E. – Klementova, M., et al.**: Urinary urea nitrogen excretion during the hyperinsulinemic euglycemic clamp in type 1 diabetic patients and healthy subjects. *Physiol Res*, 2008, 57, s. 247–252.
- 31 **Smith, D. – Rossetti, L. – Ferrannini, E., et al.**: In vivo glucose metabolism in the awake rat: tracer and insulin clamp studies. *Metabolism*, 1987, 36, s. 1167–1174.
- 32 **Porcellati, F. – Lucidi, P. – Rossetti, P., et al.**: Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus. *Diabetes Care*, 2011, 34, s. 2521–2523.
- 33 **Arnolds, S. – Kuglin, B. – Kapitza, C., et al.**: How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin

- therapy in type 2 diabetes. *Int J Clin Pract*, 2010, 64, s. 1415–1424.
- 34 Gough, S. C. – Harris, S. – Woo, V., et al.: Insulin degludec: overview of a novel ultra long-acting basal insulin. *Diabetes Obes Metab*, 2013, 15, s. 301–309.
- 35 Heise, T. – Hovelmann, U. – Nosek, L., et al.: Pharmacokinetic properties of fast-acting insulin aspart administered in different subcutaneous injection regions: response to the commentary by Nuggehally R. Srinivas. *Clin Drug Investig*, 2017, 37, s. 503–509.
- 36 Gerich, J. – Becker, R. H. – Zhu, R., et al.: Fluctuation of serum basal insulin levels following single and multiple dosing of insulin glargine. *Diabetes Technol Ther*, 2006, 8, s. 237–243.
- 37 Goldman, J. – Kapitzka, C. – Pettus, J., et al.: Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice. *Curr Med Res Opin*, 2017, s. 1–11.
- 38 MunozTorres, M.: Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: Advances in clinical research. *Endocrinol Nutr*, 2013.
- 39 Ritzel, R. – Roussel, R. – Bolli, G. B., et al.: Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. *Diabetes Obes Metab*, 2015, 17, s. 859–867.
- 40 Bailey, T. – Dahmen, R. – Pettus, J., et al.: Insulin glargine 300 U/ml (Gla-300) provides more stable and more evenly distributed steady-state PK/PD profiles compared with insulin degludec in type 1 diabetes. *Prezentováno na Diabetes Technology Meeting*, Bethesda, MD, USA, 11. 11. 2016.
- 41 Heise, T. – Norkov, M. – Nosek, L., et al.: Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. *Diabetes Obes Metab*, 2017, 19, s. 1032–1039.
- 42 Gerstein, H. C. – Bosch, J. – Dagenais, G. R., et al.: Basal insulin and cardiovascular and other outcomes in dysglycemia. *N Engl J Med*, 2012, 367, s. 319–328.
- 43 Heise, T. – Nosek, L. – Ronn, B. B., et al.: Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. *Diabetes*, 2004, 53, s. 1614–1620.
- 44 Renard, E. – Dubois-Laforgue, D. – Guerci, B.: Variability Study G. Non-inferiority of insulin glargine versus insulin detemir on blood glucose variability in type 1 diabetes patients: a multicenter, randomized, crossover study. *Diabetes Technology & Therapeutics*, 2011, 13, s. 1213–1218.

Fenomén úsvitu

prof. MUDr. Kateřina Štechová, Ph.D. Interní klinika FN v Motole, Praha

- 1 Ando, H. – Ushijima, K. – Shimba, S., et al.: Daily fasting blood glucose rhythm in male mice: a role of the circadian clock in the liver. *Endocrinology*, 2016, 157, s. 463–469.
- 2 Bereket, A. – Lang, C. H. – Wilson, T. A.: Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus. *Horm Metab Res*, 1999, 31, s. 172–181.
- 3 Bolli, G. B. – Gerich, J. E.: The „dawn phenomenon“ – a common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus. *N Engl J Med*, 1984, 310, s. 746–750.
- 4 Bouchonville, M. F. – Jaghab, J. J. – Duran-Valdez, E., et al.: The effectiveness and risks of programming an insulin pump to counteract the dawn phenomenon in type 1 diabetes. *Endocr Pract*, 2014, 20, s. 1290–1296.
- 5 Honma, K. – Hikosaka, M. – Mochizuki, K., et al.: Loss of circadian rhythm of circulating insulin concentration induced by high-fat diet intake is associated with disrupted rhythmic expression of circadian clock genes in the liver. *Metabolism*, 2016, 65, s. 482–491.
- 6 Monnier, L. – Colette, C. – Dunseath, G. J., et al.: The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. *Diabetes Care*, 2007, 30, s. 263–269.
- 7 Monnier, L. – Colette, C. – Dejager, S., et al.: Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern? *Diabetes Care*, 2013, 36, s. 4057–4062.
- 8 Perriello, G. – De Feo, P. – Tortorella, E., et al.: Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. *Diabetologia*, 1990, 33, s. 52–59.
- 9 Rey, G. – Reddy, A. B.: Connecting cellular metabolism to circadian clocks. *Trends Cell Biol*, 2013, 23, s. 234–241.
- 10 Shih, K. C. – Hsieh, S. H. – Kwok, C. F., et al.: Effect of growth hormone on dawn phenomenon in patients with type 2 diabetes. *Growth Factors*, 2013, 31, s. 66–73.
- 11 Schmidt, M. I. – Hadji-Georgopoulos, A. – Rendell, M., et al.: The dawn phenomenon, an early morning glucose rise: implications for diabetic intraday blood glucose variation. *Diabetes Care*, 1981, 4, s. 579–585.
- 12 Pelikánová, T. – Bartoš, V.: Sekrece inzulínu. In: Pelikánová, T. – Bartoš, V. (eds.): *Praktická diabetologie*. Maxdorf, Praha, 2011, s. 21–32.
- 13 Pelikánová, T. – Dryáková, M. – Kožnarová, R.: Léčba inzulínem. In: Pelikánová, T. – Bartoš, V. (eds.): *Praktická diabetologie*. Maxdorf, Praha, 2011, s. 228–267.
- 14 Porcellati, F. – Lucidi, P. – Bolli, G. B., et al.: Thirty Years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes. *Diabetes Care*, 2013, 36, s. 3860–3862.
- 15 The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. *JAMA*, 1996, 276, s. 1409–1415.

Ezetimib, jeho účinky a uplatnění v léčbě dyslipidemií

prof. MUDr. Hana Rosolová, DrSc. Centrum preventivní kardiologie, II. interní klinika FN a UK, Plzeň

- 1 Patrick, J. E. – Kosoglou, T. – Stauber, K. L., et al.: Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. *Drug Metab Dispos*, 2002, 30, s. 430–437.
- 2 Robinson, J. G. – Ballantyne, C. M. – Grundy, S. M., et al.: Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET Study). *Am J Cardiol*, 2009, 103, s. 1694–1702.
- 3 Gerdt, E. – Rossebø, A. B. – Pedersen, T. R., et al.: Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study). *Am J Cardiol*, 2010, 106, s. 1634–1639.
- 4 Savarese, G. – de Ferrari, G. M. – Rosano, G. M. C., et al.: Safety and efficacy of ezetimibe: A meta-analysis. *Int J Cardiol*, 2015, 201, s. 247–252.
- 5 SHARP Collaborative Group. Study of heart and renal protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9438 patients with chronic kidney disease. *Am Heart J*, 2010, 160, s. 785–794.
- 6 Cannon, C. P. – Blazing, M. A. – Giugliano, R. P., et al.: Ezetimibe added to statin therapy after acute coronary syndromes. *NEJM*, 2015, 372, s. 2387–2397.
- 7 Winkler, K. – Jacob, S. – Müller-Schewe, T., et al.: Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus. *Atherosclerosis*, 2012, 220, s. 189–193.
- 8 Takase, H. – Dohi, Y. – Okado, T., et al.: Effects of ezetimibe on visceral fat in the metabolite syndrome: a randomised controlled study. *Eur J Clin Invest*, 2012, 42, s. 1287–1294, DOI: 10.1111/eji.12000.
- 9 Hiramitsu, S. – Miyagishima, K. – Ishii, J., et al.: The effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load. *J Cardiol*, 2012, 60, s. 395–400.
- 10 Ushio, M. – Nishio, Y. – Sekine, O., et al.: Ezetimibe prevents hepatic steatosis induced by a high-fat but not a high-fructose diet. *Am J Physiol Endocrinol Metab*, 2013, 305, s. E293–E304.
- 11 Bohula, E. A. – Giugliano, R. P. – Cannon, C. P., et al.: Achievement of dual low-LDL cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. *Circulation*, 2015, 132, s. 1224–1233.
- 12 Pearson, T. A. – Ballantyne, C. M. – Veltri, E., et al.: Pooled analyses of effects on C-reactive protein and LDL-cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe addend to baseline statin therapy. *Am J Cardiol*, 2009, 103, s. 369–374.
- 13 Murphy, S. A. – Cannon, C. P. – Blazing, M. A., et al.: Reduction in total cardiovascular events with ezetimibe/simvastatin; post-acute coronary syndrome; The IMPROVE-IT Trial. *J Am Coll Cardiol*, 2016, 67, s. 353–361.
- 14 Bohula, E. A. – Morrow, D. A. – Giugliano, R. P., et al.: Atherothrombotic risk stratification and ezetimibe for secondary prevention. *J Am Coll Cardiol*, 2017, 69, s. 911–921.
- 15 Tsujita, K. – Sugiyama, S. – Sumida, H., et al.: Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention. The Multicenter Randomized Controlled PRECISE-IVUS Trial. *J Am Coll Cardiol*, 2015, 66, s. 495–507.
- 16 Tsujita, K. – Yamanaga, K. – Komura, N., et al.: Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: Subanalysis of PRECISE-IVUS trial. *Atherosclerosis*, 2016, 251, s. 367–372.

Úspěchy v léčbě dyslipoproteinemií

prof. MUDr. Helena Vaverková, CSc.

III. interní klinika – nefrologická, revmatologická a endokrinologická, LF UP a FN Olomouc

- 1 Cholesterol Treatment Trialists' (CTT) Collaboration; Baigent, C. – Blackwell, L. – Emberson, J., et al.: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet*, 2010, 376, s. 1670–1681.
- 2 Ference, B. A. – Yoo, W. – Alesh, I., et al.: Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. *J Am Coll Cardiol*, 2012, 60, s. 2631–2639.
- 3 Cholesterol Treatment Trialists' (CTT) Collaborators; Mihaylova, B. – Emberson, J. – Blackwell, L., et al.: The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet*, 2012, 380, s. 581–590.
- 4 Nissen, S. E. – Tuzcu, E. M. – Sipahi, I., et al.: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. *JAMA*, 2004, 291, s. 1071–1080.
- 5 Nissen, S. E. – Nicholls, S. J. – Sipahi, I., et al.: ASTEROID Investigators: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. *JAMA*, 2006, 295, s. 1556–1565.
- 6 Cannon, C. P. – Blazing, M. A. – Giugliano, R. P., et al.: Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med*, 2015, 372, s. 2387–2397.

- 7 Sabatine, M. S. – Giugliano, R. P. – Keech, A. C., et al.; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*, 2017, 376, s. 1713–1722.
- 8 Nicholls, S. J. – Puri, R. – Anderson, T., et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: The GLAGOV Randomized Clinical Trial. *JAMA*, 2016, 316, s. 2373–2384.
- 9 Robinson, J. G. – Rosenson, R. S. – Farnier, M., et al. Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials. *J Am Coll Cardiol*, 2017, 69, s. 471–482.
- 10 Ridker, P. M. – Tardif, J. C. – Amarenco, P., et al.; SPIRE Investigators. Lipid-reduction variability and antidrug-antibody formation with bococizumab. *N Engl J Med*, 2017, 376, s. 1517–1526.
- 11 Ray, K. K. – Landmesser, U. – Leiter, L. A., et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. *N Engl J Med*, 2017, 376, s. 1430–1440.
- 12 Briel, M. – Ferreira-Gonzalez, I. – You, J. J., et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. *BMJ*, 2009, 338, s. b92.
- 13 HPS3/TIMI55-REVEAL Collaborative Group. Effects of anacetrapib in patients with atherosclerotic vascular disease. *N Engl J Med*, 2017, 376, doi:10.1056/NEJMoa1706444.
- 14 Varbo, A. – Benn, M. – Nordestgaard, B. G. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. *Pharmacol Ther*, 2014, 141, s. 358–367.
- 15 Varbo, A. – Benn, M. – Tybjaerg-Hansen, A., et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. *J Am Coll Cardiol*, 2013, 61, s. 427–436.
- 16 Jun, M. – Foote, C. – Lv, J., et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. *Lancet*, 2010, 375, s. 1875–1884.
- 17 Sacks, F. M. – Carey, V. J. – Fruchart, J. C. Combination lipid therapy in type 2 diabetes. *N Engl J Med*, 2010, 363, s. 692–694; autorská odpověď s. 694–695.
- 18 Ishibashi, S. – Yamashita, S. – Arai, H., et al.; K-877-04 Study Group. Effects of K-877, a novel selective PPAR α modulator (SPPAR α), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. *Atherosclerosis*, 2016, 249, s. 36–43.
- 19 Arai, H. – Yamashita, S. – Yokote, K., et al.; K-877 Study Group. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPAR α), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. *Atherosclerosis*, 2017, 261, s. 144–152.
- 20 Yang, X. – Lee, S. R. – Choi, Y. S., et al. Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results. *J Lipid Res*, 2016, 57, s. 706–713.
- 21 Dewey, F. E. – Gusarova, V. – Dunbar, R. L., et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. *N Engl J Med*, 2017, 377, s. 211–221.
- 22 Graham, M. J. – Lee, R. G. – Brandt, T. A., et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. *N Engl J Med*, 2017, 377, s. 222–232.

Antikoagulační léčba hluboké žilní trombózy a plicní embolie

doc. MUDr. Jaromír Chlumský, Ph.D. Interní klinika 2. LF UK a FN Motol, Praha

- 1 Oake, N. – Fergusson, D. A. – Forster, A. J., et al. Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. *CMAJ*, 2007, 176, s. 1589–1594.
- 2 The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. *N Engl J Med*, 2010, 363, s. 2499–2510.
- 3 The EINSTEIN Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. *N Engl J Med*, 2012, 366, s. 1287–1297.
- 4 Buller, H. R. Oral rivaroxaban for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN DVT and EINSTEIN PE studies. *Blood (ASH Annual Meeting Abstracts)*, 2012, 120, abstrakt 20.
- 5 Schulman, S. – Kearon, C. – Kakkar, A. K., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. *N Engl J Med*, 2009, 361, s. 2342–2352.
- 6 Schulman, S. – Kakkar, A. K. – Schellong, S. M., et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). *Blood (ASH Annual Meeting Abstracts)*, 2011, 118, s. 205.
- 7 Agnelli, G. – Buller, H. R. – Cohen, A., et al. Oral apixaban for the treatment of acute venous thromboembolism. *N Engl J Med*, 2013, 369, s. 799–808.
- 8 Buller, H. R. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. *N Engl J Med*, 2013, DOI: 10.1056/NEJMoa1306638.
- 9 Fox, B. D. – Kahn, S. R. – Langleben, D., et al. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted in direct meta-analysis of randomised controlled trials. *BMJ*, 2012, 345, s. 7498–7504.
- 10 Martinelli, I. – Lensing, W. A. – Middeldorp, S., et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. *Blood*, 2016, 127, s. 1417–1425.
- 11 Mahé, I. – Sterpu, R. – Bertoletti, L., et al. Long-term anticoagulant therapy of patients with venous thromboembolism. What are the practices? *PLoS ONE*, 2015, 10, s. e0128741. Dostupné z: <https://doi.org/10.1371/journal.pone.0128741>, vyhledáno 5. 9. 2017.
- 12 Weitz, J. I. – Lensing, A. W. A. – Prins, M. H., et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. *N Engl J Med*, 2017, 376, s. 1211–1222.

Léčba akutní ischemické cévní mozkové příhody

MUDr. Jaroslava Paulasová Schwabová, Ph.D. Neurologická klinika 2. LF UK a FN Motol, Laboratoř sportovní motoriky, Fakulta tělesné výchovy a sportu UK, Praha
MUDr. Aleš Tomek, Ph.D., FESO Neurologická klinika 2. LF UK a FN Motol, Praha

- 1 Rabinstein, A. A. Treatment of acute ischemic stroke. *Continuum (Minneapolis)*, 2017, 23, s. 62–81.
- 2 Jauch, E. C., et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*, 2013, 44, s. 870–947.
- 3 Wardlaw, J. M., et al. Thrombolysis for acute ischaemic stroke. *Cochrane Database Syst Rev*, 2014, 7, s. CD000213.
- 4 Hacke, W., et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. *N Engl J Med*, 2008, 359, s. 1317–1329.
- 5 Demaerschalk, B. M., et al. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*, 2016, 47, s. 581–641.
- 6 Seet, R. C. – Rabinstein, A. A. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions. *Cerebrovasc Dis*, 2012, 34, s. 106–114.
- 7 Derex, L. – Nighoghossian, N. Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update. *J Neurol Neurosurg Psychiatry*, 2008, 79, s. 1093–1099.
- 8 Frontera, J. A., et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. *Neurocrit Care*, 2016, 24, s. 6–46.
- 9 Broderick, J. P., et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. *N Engl J Med*, 2013, 368, s. 893–903.
- 10 Ciccone, A. – Valvassori, L. Endovascular treatment for acute ischemic stroke. *N Engl J Med*, 2013, 368, s. 2433–2434.
- 11 Kidwell, C. S. – Jahan, R. – Saver, J. L. Endovascular treatment for acute ischemic stroke. *N Engl J Med*, 2013, 368, s. 2434–2435.
- 12 Berkhemer, O. A., et al. A randomized trial of intraarterial treatment for acute ischemic stroke. *N Engl J Med*, 2015, 372, s. 11–20.
- 13 Goyal, M., et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. *N Engl J Med*, 2015, 372, s. 1019–1030.
- 14 Campbell, B. C., et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. *N Engl J Med*, 2015, 372, s. 1009–1018.
- 15 Saver, J. L., et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. *N Engl J Med*, 2015, 372, s. 2285–2295.
- 16 Jovin, T. G., et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. *N Engl J Med*, 2015, 372, s. 2296–2306.
- 17 Bracard, S., et al. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. *Lancet Neurol*, 2016, 15, s. 1138–1147.
- 18 Goyal, M., et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. *Lancet*, 2016, 387, s. 1723–1731.
- 19 van den Berg, L. A., et al. Type of anesthesia and differences in clinical outcome after intra-arterial treatment for ischemic stroke. *Stroke*, 2015, 46, s. 1257–1262.
- 20 Manawadu, D., et al. A case-controlled comparison of thrombolysis outcomes between wake-up and known time of onset ischemic stroke patients. *Stroke*, 2013, 44, s. 2226–2231.
- 21 Thomalla, G. – Gerloff, C. Treatment concepts for wake-up stroke and stroke with unknown time of symptom onset. *Stroke*, 2015, 46, s. 2707–2713.
- 22 Khatri, P. – Conaway, M. R. – Johnston, K. C. Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke. *Stroke*, 2012, 43, s. 560–562.
- 23 Schonewille, W. J., et al. Treatment and outcomes of acute basilar artery occlusion in the Basilar Artery International Cooperation Study (BASICS): a prospective registry study. *Lancet Neurol*, 2009, 8, s. 724–730.
- 24 Singer, O. C., et al. Mechanical recanalization in basilar artery occlusion: the ENDOSTROKE study. *Ann Neurol*, 2015, 77, s. 415–424.

Dna – častý problém, léčebné možnosti

doc. MUDr. Petr Němec, Ph.D.

Revmatologická ambulance II. interní kliniky, FN u sv. Anny v Brně a LF MU, Brno

- 1 Richette, P. – Doherty, M. – Pascual, E., et al.: 2016 updated EULAR evidence-based recommendations for the management of gout. *Ann Rheum Dis*, 2017, 76, s. 29–42.
- 2 Campion, E. W. – Glynn, R. J. – DeLabry, L. O.: Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. *Am J Med*, 1987, 82, s. 421–426.
- 3 Stack, A. G. – Hanley, A. – Casserly, L. F., et al.: Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. *QJM*, 2013, 106, s. 647–658.
- 4 Neogi, T. – Jansen, T. L. – Dalbeth, N., et al.: 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Ann Rheum Dis*, 2015, 74, s. 1789–1798.
- 5 Ahern, M. J. – Reid, C. – Gordon, T. P., et al.: Does colchicine work? The results of the first controlled study in acute gout. *Aust NZ J Med*, 1987, 17, s. 301–304.
- 6 Terkeltaub, R. A. – Furst, D. E. – Bennett, K., et al.: High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. *Arthritis Rheum*, 2010, 62, s. 1060–1068.
- 7 Yeomans, N. D. – Tulassay, Z. – Juhász, L., et al.: A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. *N Engl J Med*, 1998, 338, s. 719–726.
- 8 Khanna, D. – Fitzgerald, J. D. – Khanna, P. P., et al.: 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care Res (Hoboken)*, 2012, 64, s. 1431–1446.
- 9 Sivera, F. – Andrés, M. – Carmona, L., et al.: Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. *Ann Rheum Dis*, 2014, 73, s. 328–335.
- 10 Schumacher, H. R. Jr. – Becker, M. A. – Wortmann, R. L., et al.: Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. *Arthritis Rheum*, 2008, 59, s. 1540–1548.
- 11 Becker, M. A. – Schumacher, H. R. Jr. – Wortmann, R. L., et al.: Febuxostat compared with allopurinol in patients with hyperuricemia and gout. *N Engl J Med*, 2005, 353, s. 2450–2461.
- 12 Becker, M. A. – Schumacher, H. R. – MacDonald, P. A., et al.: Clinical efficacy and safety of successful long term urate lowering with febuxostat or allopurinol in subjects with gout. *J Rheumatol*, 2009, 36, s. 1273–1282.
- 13 Schumacher, H. R. Jr. – Becker, M. A. – Lloyd, E., et al.: Febuxostat in the treatment of gout: 5-year findings of the FOCUS efficacy and safety study. *Rheumatology*, 2009, 48, s. 188–194.
- 14 Becker, M. A. – Schumacher, H. R. Jr. – Wortmann, R. L., et al.: Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. *Arthritis Rheum*, 2005, 52, s. 916–923.
- 15 Becker, M. A. – Schumacher, H. R. – Espinoza, L. R., et al.: The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. *Arthritis Res Ther*, 2010, 12, s. R63.

Význam kolchicinu v akutní a dlouhodobé terapii dny

doc. MUDr. Petr Bradna, CSc.

II. interní gastroenterologická klinika, subkatedra revmatologie, LF a FN Hradec Králové

- 1 Alvarez-Larrie, B. – Macaron-Vincente, J.: Uric acid and evolution. *Rheumatology*, 2010, 49, s. 2010–2015.
- 2 Roddy, E. – Choi, H.: Epidemiology of gout. *Rheum Dis Clin North Am*, 2014, 40, s. 155–175.
- 3 Wallace, S. J. – Robinson, H. – Masi, A. T., et al.: Preliminary criteria for the classification of the acute arthritis of primary gout. *Arthritis And Rheumatism*, 1977, 20, s. 895–900.
- 4 Chhana, A. – Doyle, A. – Sevaio, A., et al.: Advanced imaging assessment of gout: comparison of dual-energy CT and MRI with anatomical pathology. *Ann Rheum Dis Published Online*, doi:10.1136/annrheumdis-2017-211343.
- 5 Bongartz, T. – Glazebrook, K. N. – Kavros, S. J., et al.: Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study. *Ann Rheum Dis*, 2015, 74, s. 1072–1077.
- 6 Kiltz, U. – Smolen, J. – Bardin, T., et al.: Treat to target (T2T) recommendation for gout. *Ann Rheum Dis*, 2017, 76, s. 632–638, doi:10.1136/annrheumdis-2016-209467.
- 7 Richette, P. – Doherty, M. – Pascual, E., et al.: 2016 updated EULAR evidence-based recommendations for the management of gout. *Ann Rheum Dis*, 2016, 0, s. 1–14, doi:10.1136/annrheumdis-2016-209707.
- 8 Pavelka, K.: Doporučení České revmatologické společnosti pro léčbu dnavé artritidy. *Čes Revmatol*, 2012, 2, s. 82–92.
- 9 Khanna, D. – Fitzgerald, J. D. – Khanna, P. P., et al.: 2012 American College of Rheumatology guidelines for management of gout. Part: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care & Research*, 2012, 64, s. 1431–1446.
- 10 Grimaldi-Bensouda, L. – Alperovitch, A. – Aubrun, E., et al.: Impact of allopurinol on risk of myocardial infarction. *Ann Rheum Dis*, 2015, 74, s. 836–842.
- 11 Abraham, A. – Drory, V. E.: Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis. *J Neuro*, 2014, 261, s. 1133–1138.
- 12 Dalbeth, N. – House, M. E. – Aati, O., et al.: Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study. *Ann Rheum Dis*, 2015, 74, s. 908–911.
- 13 Terkeltaub, R. A. – Furst, D. E. – Bennett, K., et al.: High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. *Arthritis Rheum*, 2010, 62, s. 1060–1068.
- 14 Leung, Y. Y. – Hui, L. L. Y. – Kraus, V.: Colchicine – update on mechanisms of action and therapeutic uses. *Semin Arthritis Rheum*, 2015, 45, s. 341–350.
- 15 Khanna, D. – Khanna, P. P. – Fitzgerald, J. D., et al.: 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. *Arthritis Care & Research*, 2012, 64, s. 1447–1461.
- 16 Clarson, L. E. – Hider, S. L. – Belcher, J., et al.: Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK Clinical Practice Research Datalink. *Ann Rheum Dis*, 2015, 74, s. 642–647.
- 17 Roughley, M. J. – Belcher, J. – Mallen, C. D., et al.: Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. *Arthritis Research & Therapy*, 2015, 17, s. 90–102.

Střevní mikrobiota

doc. MUDr. Darina Kohoutová, Ph.D. | prof. MUDr. Jan Bureš, CSc., FCMA

II. interní gastroenterologická klinika, LF UK a FN Hradec Králové

- 1 Lepage, P.: The human gut microbiota: Interactions with the host and dysfunctions. *Rev Mal Respir*, 2017, Epub před tiskem.
- 2 Saei, A. A. – Barzegari, A.: The microbiome: the forgotten organ of the astronaut's body – probiotics beyond terrestrial limits. *Future Microbiol*, 2012, 7, s. 1037–1046.
- 3 Quigley, E. M.: Prebiotics and probiotics; modifying and mining the microbiota. *Pharmacol Res*, 2010, 61, s. 213–218.
- 4 O'Keefe, S. J.: Nutrition and colonic health: the critical role of the microbiota. *Curr Opin Gastroenterol*, 2008, 24, s. 51–58.
- 5 Pascal, V. – Pozuelo, M. – Borruel, N., et al.: A microbial signature for Crohn's disease. *Gut*, 2017, 66, s. 813–822.
- 6 Kohoutová, D. – Rejchrt, S. – Drahošová, M., et al.: *Střevní mikrobiota u idiopatických střevních zánětů a kolorektálních neoplazií*. Praha, Nucleus HK, 2013.
- 7 Kim, D. H. – Jin, Y. H.: Intestinal bacterial beta-glucuronidase activity of patients with colon cancer. *Arch Pharm Res*, 2001, 24, s. 564–567.
- 8 Reddy, B. S. – Mangat, S. – Weisburger, J. H., et al.: Effect of high-risk diets for colon carcinogenesis on intestinal mucosal and bacterial beta-glucuronidase activity in F344 rats. *Cancer Res*, 1977, 37, s. 3533–3536.
- 9 Takada, H. – Hirooka, T. – Hiramoto, Y., et al.: Effect of betagluconidase inhibitor on azoxymethane-induced colonic carcinogenesis in rats. *Cancer Res*, 1982, 42, s. 331–334.
- 10 Bureš, J. – Cyrany, J. – Kohoutová, D., et al.: Small intestinal bacterial overgrowth syndrome. *World J Gastroenterol*, 2010, 16, s. 2978–2990.
- 11 Sidhu, M. – van der Poorten, D.: The gut microbiome. *Aust Fam Physician*, 2017, 46, s. 206–211.
- 12 Eze, P. – Balsells, E. – Kyaw, M. H., et al.: Risk factors for Clostridium difficile infections – an overview of the evidence base and challenges in data synthesis. *J Glob Health*, 2017, 7, s. 010417.
- 13 Gómez, S. – Chaves, F. – Orellana, M. A.: Clinical, epidemiological and microbiological characteristics of relapse and re-infection in Clostridium difficile infection. *Anaerobe*, 2017, 48, s. 147–151.
- 14 Knip, M. – Siljander, H.: The role of the intestinal microbiota in type 1 diabetes mellitus. *Nat Rev Endocrinol*, 2016, 12, s. 154–167.
- 15 Brown, C. T. – Davis-Richardson, A. G., et al.: Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. *PLoS One*, 2011, 6, s. e25792.
- 16 Duranti, S. – Ferrario, C. – van Sinderen, D., et al.: Obesity and microbiota: an example of an intricate relationship. *Genes Nutr*, 2017, 12, s. 18.
- 17 Most, J. – Goossens, G. H. – Reijnders, D., et al.: Gut microbiota composition strongly correlates to peripheral insulin sensitivity in obese men but not in women. *Benef Microbes*, 2017, 8, s. 557–562.
- 18 Seganfredo, F. B. – Blume, C. A. – Moehlecke, M., et al.: Weight-loss interventions and gut microbiota changes in overweight and obese patients: a systematic review. *Obes Rev*, 2017, 18, s. 832–851.
- 19 Sears, C. L. – Islam, S. – Saha, A., et al.: Association of enterotoxigenic Bacteroides fragilis infection with inflammatory diarrhea. *Clin Infect Dis*, 2008, 47, s. 797–803.
- 20 Heavey, P. M. – Rowland, I. R.: Microbial-gut interactions in health and disease. *Gastrointestinal cancer. Best Pract Res Clin Gastroenterol*, 2004, 18, s. 323–336.
- 21 Kornbluth, A. A. – Danzig, J. B. – Bernstein, L. H.: Clostridium septicum infection and associated malignancy. Report of 2 cases and review of the literature. *Medicine (Baltimore)*, 1989, 68, s. 30–37.

- 22 Cummings, J. H. – Pomare, E. W. – Branch, W. J., et al.: Short chain fatty acids in human large intestine, portal, hepatic and venous blood. *Gut*, 1987, 28, s. 1221–1227.
- 23 Donohoe, D. R. – Garge, N. – Zhang, X., et al.: The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. *Cell Metab*, 2011, 13, s. 517–526.
- 24 Bultman, S. J.: Molecular pathways: gene-environment interactions regulating dietary fiber induction of proliferation and apoptosis via butyrate for cancer prevention. *Clin Cancer Res*, 2014, 20, s. 799–803.
- 25 Donohoe, D. R. – Collins, L. B. – Wali, A., et al.: The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. *Mol Cell*, 2012, 48, s. 612–626.
- 26 Cascales, E. – Buchanan, S. K. – Duché, D., et al.: Colicin biology. *Microbiol Mol Biol Rev*, 2007, 71, s. 158–229.
- 27 Bureš, J. – Horák, V. – Burešová, E., et al.: Colicinogeny in chronic inflammatory bowel disease. *Scand J Gastroenterol*, 1986, 21, s. 819–823.
- 28 Šmarda, J. – Obdržálek, V. – Táborský, I., et al.: The cytotoxic and cytotoxic effect of colicin E3 on mammalian tissue cells. *Folia Microbiol*, 1978, 23, s. 272–277.
- 29 Cornut, G. – Fortin, C. – Soulières, D.: Antineoplastic properties of bacteriocins: revisiting potential active agents. *Am J Clin Oncol*, 2008, 31, s. 399–404.
- 30 Kohoutova, D. – Smajs, D. – Moravkova, P., et al.: Escherichia coli strains of phylogenetic group B2 and D and bacteriocin production are associated with advanced colorectal neoplasia. *BMC Infect Dis*, 2014, 14, s. 733.

Novinky ve farmakoterapii bolesti

MUDr. Marek Hakl, Ph.D. Klinika algeziologie a preventivní péče, Medicinecare, s. r. o.,
Chirurgická klinika FN Brno a LF MU, Brno

- 1 Lemmel, E. – Leeb, B. – Bast, J., et al.: Patient and physician satisfaction with Acetofenac: Results of the European observational cohort study current Med Res Op, 2002, 18, s. 146–153.
- 2 Pasero, G. – Marcolongo, R. – Serni, U., et al.: A multi-centre, double-blind comparative study of the efficacy and safety of acetofenac and diclofenac in the treatment of rheumatoid arthritis. *Curr Med Res Opin*, 1995, 13, s. 305–315.
- 3 Webster, L. R.: Breakthrough pain in the management of chronic persistent pain syndromes. *Am J Manag Care*, 2008, 14, s. 116–122.
- 4 Dickman, A.: Integrated strategies for the successful management of breakthrough cancer pain. *Curr Opin Support Palliat Care*, 2011, 5, s. 8–14.
- 5 Fortner, B. V. – Okon, T. A. – Portenoy, R. K.: A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. *J Pain*, 2002, 3, s. 38–44.
- 6 Davis, M.: Fentanyl for breakthrough pain: a systematic review. *Expert Rev Neurother*, 2011, 11, s. 1197–1216.
- 7 Backonja, M. – Wallace, M. – Blonsky, R., et al.: NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. *Lancet Neurol*, 2008, 7, s. 1106–1112.
- 8 Simpson, D. – Brown, S. – Tobias, J.: Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. *Neurology*, 2008, 70, s. 2305–2313.

Přínos suché krevní kapky v diagnostice dědičných metabolických onemocnění

Ing. Karolína Pešková Klinika dětského a dorostového lékařství VFN a 1. LF UK, Praha

- 1 www.novorozeneckyscreening.cz
- 2 Grüner, N. – Stambouli, O. – Ross, R. S.: Dried blood spots – preparing and processing for use in immunoassays and in molecular techniques. *J Vis Exp*, 2015, 97, s. 52619.
- 3 Zakaria, R. – Allen, K. J. – Koplín, J. J., et al.: Advantages and challenges of dried blood spot analysis by mass spectrometry across the total testing process. *EJIFCC*, 2016, 27, s. 288–317.

Extrahepatální manifestace infekce HCV

prof. MUDr. Petr Husa, CSc. Klinika infekčních chorob LF MU a FN Brno

- 1 World Health Organization. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Updated version April 2016. Dostupné z: www.who.int/hiv/topics/hepatitis/en, vyhledáno 10. 10. 2017.
- 2 Tillmann, H. L. – McHutchison, J. G. – Hepatitis C. In: Boyer, T. D. – Manns, M. P. – Sanyal, A.: *Zakim and Boyer's Hepatology*. 6. vydání. Elsevier Saunders, Philadelphia, 2012, s. 574–576.
- 3 Cacoub, P. – Gragnani, L. – Comarmond, C., et al.: Extrahepatic manifestations of chronic hepatitis C virus infection. *Dig Liver Dis*, 2014, 46, suppl. 5, s. S165–S173.
- 4 Younossi, Z. – Park, H. – Henry, L., et al.: Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. *Gastroenterology*, 2016, 150, s. 1599–1608.
- 5 EASL Recommendations on Treatment of Hepatitis C 2016. *J Hepatol*, 2016. Dostupné z: www.easl.eu.
- 6 Negro, F. – Forton, D. – Craxi, A., et al.: Extrahepatic morbidity and mortality of chronic hepatitis C. *Gastroenterology*, 2015, 149, s. 1345–1360.
- 7 Smith-Palmer, J. – Cerri, K. – Valentine, W.: Achieving sustained virological response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. *BMC Infect Dis*, 2015, 15, s. 19, doi: 10.1186/s12879-015-0748-8.
- 8 Pascual, M. – Perrin, L. – Giostra, E., et al.: Hepatitis C virus in patients with cryoglobulinemia type II. *J Infect Dis*, 1990, 162, s. 569–570.
- 9 Agnello, V. – Chung, R. T. – Kaplan, L. M.: A role for hepatitis C virus infection in type II cryoglobulinemia. *N Engl J Med*, 1992, 327, s. 1490–1495.
- 10 Misiani, R. – Bellavita, P. – Fenili, D., et al.: Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. *Ann Intern Med*, 1992, 117, s. 573–577.
- 11 Pawlotsky, J. M. – Ben Yahia, M. – Andre, C., et al.: Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. *Hepatology*, 199, 19, s. 841–848.
- 12 American Association for the study of Liver Diseases. AASLD recommendation for testing, managing, and treating hepatitis C. Dostupné z: www.hcvguidelines.org, vyhledáno 3. 8. 2016.
- 13 Schott, P. – Hartmann, H. – Ramadori, G.: Hepatitis C virus-associated mixed cryoglobulinemia. Clinical manifestations, histopathological changes, mechanism of cryoprecipitation and options of treatment. *Histology and Histopathology*, 2001, 16, s. 1275–1285.
- 14 Cicardi, M. – Cesana, B. – Del Ninno, E., et al.: Prevalence and risk factors for the presence of serum cryoglobulins in patients with chronic hepatitis C. *J Viral Hepatol*, 2000, 7, s. 138–143.
- 15 Hoofnagle, J. H. – Heller, T.: Hepatitis C. In: Zakim, D. – Boyer, T. D.: *Hepatology. A Textbook of Liver Disease*. 4. vydání. Saunders, Philadelphia, 2003, s. 1017–1062.
- 16 Fraňková, S. – Urbánek, P. – Šperl, J., et al.: Diagnostický a terapeutický postup chronické infekce virem hepatitidy C u pacientů s chronickým onemocněním ledvin. *Aktuality v nefrologii*, 2016, 22, s. 63–65.

Diagnostika a medikamentózní terapie exokrinní pankreatické nedostatečnosti u osob s chronickou pankreatitidou v ČR – dle UEG doporučení

prof. MUDr. Petr Dítě, DrSc. | MUDr. Martin Blaho

Interní klinika Fakultní nemocnice Ostrava, Lékařská fakulta Ostravské Univerzity, Ostrava

MUDr. Martina Bojková | MUDr. Tomáš Kuka Interní klinika Fakultní nemocnice Ostrava

- 1 Jupp, J. – Fine, D. – Johnson, C. D.: The epidemiology and socioeconomic impact of chronic pancreatitis. *Best Pract Res Clin Gastroenterol*, 2010, 24, s. 219–231.
- 2 Levy, P. – Dominguez-Munoz, E. – Imrie, C., et al.: Epidemiology of chronic pancreatitis. Burden of the disease and consequences. *United European Gastroenterol J*, 2014, 2, s. 345–354.
- 3 Dítě, P. – Starý, K. – Novotný, I., et al.: Incidence of chronic pancreatitis in Czech Republic. *Eur J Gastroenterol*, 2001, 13, s. 749–750.
- 4 Whitcomb, D. C. – Frulloni, L. – Garg, P., et al.: Chronic pancreatitis. An International draft consensus proposal for a mechanistic definition. *Pancreatology*, 2016, 16, s. 218–224.
- 5 Hoffmeister, A. – Mayerle, J. – Beglinger, C., et al.: Definition, etiology diagnostic examinations, medical, endoscopic and surgical management of chronic pancreatitis. *Gastroenterol*, 2015, 53, s. 1443–1495.
- 6 Issa, I. – Kempeneers, M. A. – van Santvoort, H., et al.: Diagnostic performance of imaging modalities in chronic pancreatitis. A systematic reviews and meta-analysis. *European Radiology*, 2017, 27, s. 3820–3844.
- 7 Anderson, S. W. – Soto, J. A.: Pancreatic duct evaluation. Accuracy of portal venous phase 64 MDCT. *Abdomen Imaging*, 2009, 34, s. 55–64.
- 8 Hellerhoff, K. J. – Helberger, H. – Rosch, T., et al.: Dynamic MR pancreatography after secretin administration. Image quality and diagnostic accuracy. *AJR*, 2002, 179, s. 121–129.
- 9 Manfred, N. – Lucdu, V. – Gui, B., et al.: Idiopathic chronic pancreatitis in children. MR cholangiopancreatography after secretin administration. *Radiology*, 2002, 224, s. 675–682.
- 10 Shmulewicz, S. – Teefey, S. A. – Robinson, B. S.: Factors affecting image quality and diagnostic efficacy in abdominal sonography. A prospective study of 140 patients. *J Clin Ultrasound*, 1993, 21, s. 623–630.
- 11 Postema, M. – Gilja, O. H.: Contrast-enhanced and targeted ultrasound. *WJG*, 2011, 17, s. 28–41.
- 12 Kersting, S. – Roth, J. – Bunk, A.: Transabdominal contrast enhanced ultrasonography of pancreatic cancer. *Pancreatology*, 2011, 11, s. S20–S27.
- 13 Iglesias-Garcia, J. – Lariño-Noia, J.: Endoscopic ultrasound in the diagnosis of chronic pancreatitis. The Rosemont classification. *Gastrointest Endosc*, 2009, 69, s. 1251–1261.
- 14 Catalano, M. F. – Sahai, A. – Levy, M., et al.: EUS-based criteria for the diagnosis of chronic pancreatitis. The Rosemont classification. *Gastrointest Endosc*, 2009, 69, s. 1251–1261.
- 15 Shomosegawa, T. – Chari, S. – Frulloni, L., et al.: International consensus diagnostic criteria for autoimmune pancreatitis: Guidelines of the International Association of Pancreatology. *Pancreas*, 2011, 40, s. 352–358.
- 16 Pezzilli, R. – Andriulli, A. – Bassi, C., et al.: Exocrine pancreatitis in adults. A shared position statement of the Italian association for the study of the pancreas. *WJG*, 2013, 19, s. 7930–7946.
- 17 Lankich, P. G. – Seidenstricker, F. – Otto, J., et al.: Secretin-pancreozymin test and endoscopic retrograde cholangio-pancreatography. Both are necessary for the diagnosis or excluding of chronic pancreatitis. *Pancreas*, 1996, 12, s. 149–152.
- 18 Layer, P. – Yamamoto, H. – Kalthof, L., et al.: The different courses of early or late-onset idiopathic and alcoholic chronic pancreatitis. *Gastroenterology*, 1994, 107, s. 1481–1487.
- 19 Chowdhury, R. – Bhutani, M. S. – Mistral, G., et al.: Comparative analysis of direct pancreatic function testing versus morphological assessment by endoscopic ultrasonography for the evaluation of chronic unexplained abdominal pain of presumed origin. *Pancreas*, 2005, 31, s. 63–68.
- 20 Lohr, J. M. – Dominguez-Muniz, E. – Rosendhl, J., et al.: United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis. *UEG Journal*, 2017, s. 1–72.
- 21 Matos, C. – Metens, T. – Deviere, J., et al.: Pancreatic duct: Morphologic and functional evaluation with dynamic MR pancreatography of the secretin stimulation. *Radiology*, 1997, 203, s. 435–451.
- 22 Lohr, J. M. – Oliver, M. R. – Frulloni, L.: Synopsis of the recent guidelines on pancreatic exocrine insufficiency. *United Euop Gastroent J*, 2013, s. 79–83.
- 23 DiMaggio, E. P. – Go, V. L. – Summerskill, V. H.: Relations between pancreatic enzyme outputs and malabsorption in severe exocrine insufficiency. *N Engl J Med*, 1973, 288, s. 813–815.
- 24 Keller, J. – Meier, V. – Wolfram, K. U., et al.: Sensitivity and specificity of an abbreviated 13C – mixed triglyceride breath test for a measurement of pancreatic exocrine function in diabetes mellitus. *UEG Journal*, 2014, 43, s. 842–848.
- 25 Dominguez-Munt, J. E. – Iglesias-Garcia, J.: Oral pancreatic enzyme substitution therapy in chronic pancreatitis: Is clinical response an appropriate marker for evaluation for therapeutic efficacy. *J Pancreas*, 2010, 11, s. 158–162.
- 26 Lindkvist, B. – Phillips, M. E. – Dominguez-Munoz, J. E., et al.: Serum nutritional markers for prediction for pancreatic exocrine insufficiency in chronic pancreatitis. *Pancreatology*, 2012, 12, s. 305–310.
- 27 Whitcomb, D. C. – Lehman, G. A. – Vasileva, G., et al.: Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery. A double-blind randomized trial. *Am J Gastroenterol*, 2010, 105, s. 2276–2286.
- 28 Dutta, S. K. – Rubin, J. – Harvey, J.: Comparative evaluation of the therapeutic efficacy of a Ph-sensitive Enteric COAted pancreatic enzyme preparation with conventional enzyme therapy in the treatment of exocrine pancreatic insufficiency. *Gastroenterology*, 1983, 84, s. 476–482.
- 29 Creutzfeld, W. – Lembcke, B. – Folsch, U., et al.: Effect of somatostatin analogue (Sandostatin) on pancreatic secretion in the humans. *Am J Med*, 1987, 82, s. 49–54.
- 30 Halm, U. – Loser, C. – Lohr, M.: A double-blind, randomized multicentre, cross-over study to prove equivalence of pancreat in minicapsules versus microspheres in exocrine pancreatic insufficiency. *Aliment Pharmacol Ther*, 1999, 13, s. 951–957.